Sendai virus-based immunoadjuvant in hydrogel vaccine intensity-modulated dendritic cells activation for suppressing tumorigenesis

Cai, 2019, Improving cancer vaccine efficiency by nanomedicine, Adv. Biosyst., 3, 18 Li, 2019, Multiantigenic nanoformulations activate anticancer immunity depending on size, Adv. Funct. Mater., 29, 1429 Shukla, 2019, A viral nanoparticle cancer vaccine delays tumor progression and prolongs survival in a HER2(+) tumor mouse model, Advanced Therapeutics, 2, 4019, 10.1002/adtp.201800139 Noh, 2017, Multifaceted immunomodulatory nanoliposomes: reshaping tumors into vaccines for enhanced cancer immunotherapy, Adv. Funct. Mater., 27, 10.1002/adfm.201605398 Fusciello, 2019, Artificially cloaked viral nanovaccine for cancer immunotherapy, Nat. Commun., 10, 5747, 10.1038/s41467-019-13744-8 Huang, 2012, A totally synthetic, self-assembling, adjuvant-free MUC1 glycopeptide vaccine for cancer therapy, J. Am. Chem. Soc., 134, 8730, 10.1021/ja211725s Patel, 2019, Development of an in situ cancer vaccine via combinational radiation and bacterial-membrane-coated nanoparticles, Adv. Mater., 31, 10.1002/adma.201902626 Lv, 2013, Suppression of breast tumor growth by DNA vaccination against phosphatase of regenerating liver 3, Gene Ther., 20, 834, 10.1038/gt.2013.5 Aravindaram, 2014, Tumor-associated antigen/IL-21-transduced dendritic cell vaccines enhance immunity and inhibit immunosuppressive cells in metastatic melanoma, Gene Ther., 21, 457, 10.1038/gt.2014.12 Nguyen, 2009, Polymeric materials for gene delivery and DNA vaccination, Adv. Mater., 21, 847, 10.1002/adma.200801478 Li, 2014, Messenger RNA vaccine based on recombinant MS2 virus-like particles against prostate cancer, Int. J. Canc., 135, 1683, 10.1002/ijc.28482 Hangalapura, 2012, CD40-targeted adenoviral cancer vaccines: the long and winding road to the clinic, J. Gene Med., 14, 416, 10.1002/jgm.1648 Yamasaki, 2013, Intravenous genetic mesothelin vaccine based on human adenovirus 40 inhibits growth and metastasis of pancreatic cancer, Int. J. Canc., 133, 88, 10.1002/ijc.27983 Zheng, 2019, Bacterium-mimicking vector with enhanced adjuvanticity for cancer immunotherapy and minimized toxicity, Adv. Funct. Mater., 29, 10.1002/adfm.201901437 Luo, 2017, A Powerful CD8(+) T-cell stimulating D-tetra-peptide hydrogel as a very promising vaccine adjuvant, Adv. Mater., 29, 10.1002/adma.201601776 Kroll, 2017, Nanoparticulate delivery of cancer cell membrane elicits multiantigenic antitumor immunity, Adv. Mater., 29, 10.1002/adma.201703969 Cao, 2014, Ultrasmall graphene oxide supported gold nanoparticles as adjuvants improve humoral and cellular immunity in mice, Adv. Funct. Mater., 24, 6963, 10.1002/adfm.201401358 Jiang, 2018, Turning the old adjuvant from gel to nanoparticles to amplify CD8(+) T cell responses, Advanced Science, 5 Wu, 2020, Potential zika vaccine: encapsulated nanocomplex promotes both T(H)1/T(H)2 responses in mice, Advanced Therapeutics, 3, 10.1002/adtp.201900197 Maeda, 2019, Poly(I:C) stimulation is superior than Imiquimod to induce the antitumoral functional profile of tumor-conditioned macrophages, Eur. J. Immunol., 49, 801, 10.1002/eji.201847888 Chen, 2019, Tumor-targeted drug and CpG delivery system for phototherapy and docetaxel-enhanced immunotherapy with polarization toward M1-type macrophages on triple negative breast cancers, Adv. Mater., 31, 10.1002/adma.201904997 Glaffig, 2018, A synthetic MUC1 anticancer vaccine containing mannose ligands for targeting macrophages and dendritic cells, ChemMedChem, 13, 25, 10.1002/cmdc.201700646 Xia, 2014, CpG oligodeoxynucleotide as immune adjuvant enhances photodynamic therapy response in murine metastatic breast cancer, J. Biophot., 7, 897, 10.1002/jbio.201300072 Verstak, 2007, Toll-like receptor signalling and the clinical benefits that lie within, Inflamm. Res., 56, 1, 10.1007/s00011-007-6093-7 Rosadini, 2017, Early innate immune responses to bacterial LPS, Curr. Opin. Immunol., 44, 14, 10.1016/j.coi.2016.10.005 Paez-Espino, 2016, Uncovering Earth’s virome, Nature, 536, 425, 10.1038/nature19094 Dong, 2020, Bioinorganic hybrid bacteriophage for modulation of intestinal microbiota to remodel tumor-immune microenvironment against colorectal cancer, Science Advances, 6, 10.1126/sciadv.aba1590 Zheng, 2019, Phage-guided modulation of the gut microbiota of mouse models of colorectal cancer augments their responses to chemotherapy, Nature Biomedical Engineering, 3, 717, 10.1038/s41551-019-0423-2 Zheng, 2018, Optically-controlled bacterial metabolite for cancer therapy, Nat. Commun., 9, 1680, 10.1038/s41467-018-03233-9 Watanabe, 2018, Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses, JCI Insight, 3, 17, 10.1172/jci.insight.99573 Kreso, 2013, Variable clonal repopulation dynamics influence chemotherapy response in colorectal cancer, Science, 339, 543, 10.1126/science.1227670 Zhan, 2019, CRISPR/Cas9 for cancer research and therapy, Semin. Canc. Biol., 55, 106, 10.1016/j.semcancer.2018.04.001 Sanchez-Rivera, 2015, Applications of the CRISPR-Cas9 system in cancer biology, Nat. Rev. Canc., 15, 387, 10.1038/nrc3950 Ura, 2014, Developments in viral vector-based vaccines, Vaccines, 2, 624, 10.3390/vaccines2030624 Lopez, 2004, TLR-independent induction of dendritic cell maturation and adaptive immunity by negative-strand RNA viruses, J. Immunol., 173, 6882, 10.4049/jimmunol.173.11.6882 Mercado-Lopez, 2013, Highly immunostimulatory RNA derived from a Sendai virus defective viral genome, Vaccine, 31, 5713, 10.1016/j.vaccine.2013.09.040 Liu, 2018, Combination Immunotherapy of MUC1 mRNA Nano-vaccine and CTLA-4 blockade effectively inhibits growth of triple negative breast cancer, Mol. Ther., 26, 45, 10.1016/j.ymthe.2017.10.020 Yang, 2018, Cancer cell membrane-coated adjuvant nanoparticles with mannose modification for effective anticancer vaccination, ACS Nano, 12, 5121, 10.1021/acsnano.7b09041 Tanaka, 2012, STING specifies IRF3 phosphorylation by TBK1 in the cytosolic DNA signaling pathway, Sci. Signal., 5, 11, 10.1126/scisignal.2002521 Shae, 2019, Endosomolytic polymersomes increase the activity of cyclic dinucleotide STING agonists to enhance cancer immunotherapy, Nat. Nanotechnol., 14, 269, 10.1038/s41565-018-0342-5 Ali, 2004, Anti-tumour therapeutic efficacy of OX40L in murine tumour model, Vaccine, 22, 3585, 10.1016/j.vaccine.2004.03.041 Bansal-Pakala, 2004, Costimulation of CD8 T cell responses by OX40, J. Immunol., 172, 4821, 10.4049/jimmunol.172.8.4821 Scaggs Huang, 2020, Safety and immunogenicity of an intranasal sendai virus-based vaccine for human parainfluenza virus type I and respiratory syncytial virus (SeVRSV) in adults, Hum. Vaccines Immunother., 17, 554, 10.1080/21645515.2020.1779517 Ge, 2017, HERP Binds TBK1 to activate innate immunity and repress virus replication in response to endoplasmic reticulum stress, J. Immunol., 199, 3280, 10.4049/jimmunol.1700376 Hiscott, 2007, Convergence of the NF-kappa B and IRF pathways in the regulation of the innate antiviral response, Cytokine Growth Factor Rev., 18, 483, 10.1016/j.cytogfr.2007.06.002 Ali, 2013, Inflammatory cytokines presented from polymer matrices differentially generate and activate DCs in situ, Adv. Funct. Mater., 23, 4621, 10.1002/adfm.201203859 Zimmer, 2005, A chimeric respiratory syncytial virus fusion protein functionally replaces the F and HN glycoproteins in recombinant Sendai virus, J. Virol., 79, 10467, 10.1128/JVI.79.16.10467-10477.2005 Bullough, 1994, Structure of influenza haemagglutinin at the pH of membrane fusion, Nature, 371, 37, 10.1038/371037a0 Marcus, 2018, Tumor-derived cGAMP Triggers a STING-mediated interferon response in non-tumor cells to activate the NK cell response, Immunity, 49, 754, 10.1016/j.immuni.2018.09.016 Janco, 2015, Tumor-infiltrating dendritic cells in cancer pathogenesis, J. Immunol., 194, 2985, 10.4049/jimmunol.1403134 Bottcher, 2018, The role of type 1 conventional dendritic cells in cancer immunity, Trends Cancer, 4, 784, 10.1016/j.trecan.2018.09.001 Gardner, 2016, Dendritic cells and cancer immunity, Trends Immunol., 37, 855, 10.1016/j.it.2016.09.006 Aspeslagh, 2016, Rationale for anti-OX40 cancer immunotherapy, Eur. J. Canc., 52, 50, 10.1016/j.ejca.2015.08.021 Murphy, 2012, An in vivo immunotherapy screen of costimulatory molecules identifies Fc-OX40L as a potent reagent for the treatment of established murine gliomas, Clin. Canc. Res., 18, 4657, 10.1158/1078-0432.CCR-12-0990 Curti, 2013, OX40 is a potent immune-stimulating target in late-stage cancer patients, Canc. Res., 73, 7189, 10.1158/0008-5472.CAN-12-4174